目的:对比瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效.方法:选择2014年1月-2015年12月于我院心血管内科住院的冠心病患者150例,按照抽签法分为瑞舒伐他汀组(72例)和阿托伐他汀组(78例).所有患者均调整生活习惯,给予抗血小板和调整血压药物等基础治疗.同时,瑞舒伐他汀组患者给予瑞舒伐他汀钙片10 mg,po,每晚1次;阿托伐他汀组患者给予阿托伐他汀钙片20 mg,po,每晚1次.两组患者均治疗6个月.比较治疗前后两组患者的血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平、颈动脉内-中膜厚度(IMT)、颈动脉斑块积分(Crouse积分)、冠状动脉狭窄程度评分(Gensini评分)和肱动脉内径变化百分率(D),记录不良反应发生情况.结果:治疗前,两组患者上述各指标比较,差异均无统计学意义(P>0.05).治疗后,两组患者的TC、TG、LDL-C、IMT、Crouse积分和Gensini评分均较治疗前显著下降,HDL-C和D值较治疗前显著上升,且瑞舒伐他汀组患者的TC、TG、LDL-C、Crouse积分和Gensini评分均显著低于阿托伐他汀组,D值显著高于阿托伐他汀组,差异均有统计学意义(P0.05). After treatment,the levels of TC,TG,LDL-C,IMT,Crouse scores and Gensini scores in 2 groups were decreased signifi-cantly,while the levels of HDL-C and D values were increased significantly,compared to before treatment;the levels of TC,TG, LDL-C,Crouse score and Gensini score in rosuvastatin group were significantly lower than atorvastatin group,and D value was significantly higher atorvastatin group,with statistical significance(P<0.05). There was no statistical significance in the levels of HDL-C or IMR between 2 groups (P<0.05). During treatment,dizziness occurred in a patient of rosuvastatin group and relieved spontaneously. Four patients in each group had slight elevation of transaminase,and could be reduced to normal after liver protec-tion treatment. CONCLUSIONS:Rosuvastatin shows more significant therapeutic efficacy than that of atorvastatin in reducing blood lipid,improving AS and vascular endothelial vasodilation in CHD patients with good satety.
展开▼
